Which startups have raised the most funding in the remote patient monitoring market?
A constantly refreshed list of the top startups in the remote patient monitoring market, ranked by cumulative funding raised

In our updated market reports, you will find everything you need
The remote patient monitoring market is becoming one of the most important parts of digital health, as providers, payers, and patients look for better ways to manage chronic conditions outside the clinic.
This list ranks the top remote patient monitoring startups by cumulative funding raised, and we update it every month to keep the dataset fresh.
The ranking includes diabetes care, cardiac monitoring, virtual wards, wearable biosensors, chronic care platforms, and hospital-at-home monitoring companies.
A quick summary table
| Metric | Value |
|---|---|
| Most funded startup | Beta Bionics, $570M raised |
| Second most funded startup | Omada Health, $542M raised |
| Largest funding round | Oviva, $220M Series D in January 2026 |
| Median funding | $40M |
| Share of funding captured by the top 10 | About 45.7% |
| Median time since last round | About 33 months |
| Startups that raised funding in the last 12 months | 22 startups |
| Remote patient monitoring startups tracked | 91 startups |
| Remote patient monitoring companies with IPO status | 8 companies |
| Remote patient monitoring companies acquired | 12 companies |
Top startups in the remote patient monitoring market ranked by total funding raised
Here is an updated table that ranks the top startups in the remote patient monitoring market based on the total amount of funding they have raised to date.
The table also includes the total number of funding rounds, the date and size of the latest round, the financing type, key investors, the startup’s current status, and a confidence score based on the data collected.
| # | Startup | What They Do | Total Raised ($) | Total Rounds | Last Round Date | Last Round Amount ($) | Last Round Type | Key Investors | Current Stage | Confidence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Beta Bionics | Automated insulin delivery | $570M | 7 | January 2025 | $17M | PIPE / Private Placement | Wellington Management, Sands Capital, Omega Funds | IPO | Strong |
| 2 | Omada Health | Virtual chronic care programs | $542M | 8 | June 2025 | $150M | IPO | Fidelity, aMoon, Wellington Management | IPO | Strong |
| 3 | Biofourmis | AI-enabled remote care platform | $461M | 6 | August 2022 | $20M | Series D extension | Intel Capital, General Atlantic, CVS Health | Active | Strong |
| 4 | Virta Health | Diabetes reversal virtual care | $402M | 7 | December 2025 | $30M | Series F | Tiger Global, Sequoia, Caffeinated Capital | Active | Strong |
| 5 | Huma | Digital health monitoring platform | $355M | 13 | April 2025 | $17M | Series D / late-stage | AstraZeneca, Hitachi Ventures, Leaps by Bayer | Active | Partial |
| 6 | Oviva | Digital chronic care | $335M | 4 | January 2026 | $220M | Series D | Kinnevik, Planet First Partners, A.P. Moller Holding | Active | Strong |
| 7 | Senseonics | Implantable glucose monitoring | $289M | 5 | May 2026 | $92M | Public Offering | NEA, Delphi Ventures, Anthem Capital | IPO | Partial |
| 8 | Twin Health | Metabolic digital twins | $283M | 5 | August 2025 | $53M | Series E | Maj Invest, ICONIQ Capital, Temasek | Active | Strong |
| 9 | Athelas | Remote care and healthcare AI | $276M | 6 | May 2026 | $70M | Growth financing | General Catalyst, Sequoia Capital, Morgan Stanley | Active | Partial |
| 10 | Biolinq | Wearable metabolic biosensors | $273M | 5 | April 2025 | $100M | Series C | Alpha Wave Ventures, RiverVest, AXA IM Alts | Active | Strong |
| 11 | DarioHealth | Chronic-condition digital care | $269M | 26 | September 2025 | $18M | Post-IPO Private Placement | Existing shareholders, healthcare investors | IPO | Partial |
| 12 | Cadence | Chronic care at home | $241M | 3 | June 2026 | $100M | Series C | Spark Capital, Thrive Capital, General Catalyst | Active | Full |
| 13 | VitalConnect | Wearable biosensor patient monitoring | $240M | 6 | February 2025 | $100M | Undisclosed / mixed equity-debt | Ally Bridge Group, EW Healthcare Partners, MVM | Active | Partial |
| 14 | FIRE1 | Heart failure monitoring device | $227M | 6 | January 2025 | $120M | Series D | Polaris Partners, Elevage Medical Technologies, Sands Capital | Active | Strong |
| 15 | Glooko | Diabetes data platform | $201M | 8 | October 2024 | $100M | Series F | Georgian, Health Catalyst Capital, Canaan | Active | Strong |
| 16 | Lark Health | AI chronic disease coaching | $170M | 5 | October 2021 | $100M | Series D | Deerfield Management, PFM Health Sciences, Franklin Templeton | Active | Partial |
| 17 | Eko Health | AI cardiac stethoscope platform | $165M | 7 | June 2024 | $41M | Series D | ARTIS Ventures, Highland Capital Partners, NTTVC | Active | Strong |
| 18 | Bigfoot Biomedical | Smart insulin systems | $149M | 4 | June 2020 | $55M | Series C | Abbott, Quadrant Capital Advisors, Janus Henderson | Acquired | Partial |
| 19 | BioIntelliSense | Medical-grade wearable patient monitoring | $140M | 4 | December 2025 | $58M | Series C | Chimera Investments, Philips, Fresenius | Active | Strong |
| 20 | Preventice Solutions | Remote cardiac monitoring services | $138M | 7 | July 2020 | $137M | Series B | Vivo Capital, Novo Holdings, Merck GHI | Acquired | Partial |
| 21 | Hello Heart | Digital heart health therapeutics | $138M | 4 | December 2023 | $70M | Series D | Stripes, IVP, Khosla Ventures | Active | Strong |
| 22 | InfoBionic | Cardiac remote monitoring platform | $135M | 7 | September 2023 | $58M | Series D | Security International Investments, Mayo Clinic, Excel Venture Management | Active | Partial |
| 23 | AliveCor | Personal ECG monitoring devices | $134M | 7 | August 2022 | Undisclosed | Series F | GE Healthcare, Khosla Ventures, Qualcomm Ventures | Active | Partial |
| 24 | Diabeloop | AI insulin delivery | $125M | 4 | March 2024 | $16M | Venture / Growth Equity | LBO France, Terumo, Innovacom | Active | Partial |
| 25 | Electronic Caregiver | AI virtual care monitoring platform | $110M | 5 | June 2025 | Undisclosed | Series D / later-stage | NM Vintage Fund, repeat investors | Active | Partial |
| 26 | Endotronix | Heart failure pressure monitoring | $102M | 2 | October 2019 | $70M | Series D | LSP, Lumira Ventures, SV Health Investors | Acquired | Partial |
| 27 | iRhythm Technologies | Wearable cardiac rhythm analytics | $99M | 10 | May 2014 | $17M | Series E | Novo A/S, Norwest Venture Partners, New Leaf Ventures | IPO | Partial |
| 28 | Bardy Diagnostics | Ambulatory cardiac monitor patch | $83M | 4 | February 2020 | $13M | Series B extension | River Cities, HealthQuest Capital, Lumira Ventures | Acquired | Partial |
| 29 | Sidekick Health | Digital therapeutics platform | $77M | 3 | May 2022 | $55M | Series B | Novator Ventures, Wellington Partners, Asabys Partners | Active | Strong |
| 30 | Sibel Health | Wireless wearable vital-sign monitoring | $72M | 2 | October 2025 | $9M | Series C extension | Steele Foundation, Dräger, Samsung Next | Active | Strong |
| 31 | Podimetrics | Diabetic foot monitoring | $72M | 5 | March 2022 | $45M | Series C | D1 Capital Partners, Medtech Convergence Fund, Polaris Partners | Active | Partial |
| 32 | Current Health | Hospital-at-home monitoring platform | $66M | 5 | April 2021 | $43M | Series B | Northpond Ventures, LRVHealth, OSF HealthCare | Active | Strong |
| 33 | Doccla | Virtual ward monitoring services | $65M | 3 | August 2024 | $45M | Series B | Lakestar, General Catalyst, Speedinvest | Active | Full |
| 34 | CoachCare | RPM and virtual care management | $60M | 4 | February 2025 | $1M | Late-stage / undisclosed | Catalyst Investors, Integrity Growth Partners, Topmark Partners | Active | Partial |
| 35 | TimeDoc Health | Virtual chronic care management | $58M | 4 | March 2022 | $49M | Series B | Aldrich Capital, Vocap, Grand Ventures | Active | Strong |
| 36 | Glytec | Diabetes insulin management software | $56M | 3 | June 2025 | $36M | Series C / Growth | Savitr Capital, Hayfin Capital Management | Active | Partial |
| 37 | Indigo Diabetes | Implantable glucose sensor | $53M | 2 | July 2020 | $45M | Series B | Fund+, Ackermans & van Haaren, imec.xpand | Active | Full |
| 38 | Cecelia Health | Virtual chronic care platform | $52M | 11 | June 2025 | $16M | Series D / Later-stage | SJF Ventures, Rittenhouse Ventures, Croft & Bender | Active | Partial |
| 39 | Biobeat | Cuffless blood pressure monitoring | $51M | 2 | December 2025 | $50M | Series B | Ally Bridge Group, OrbiMed Advisors, Elevage Medical Technologies | Active | Strong |
| 40 | BeatO | Smartphone diabetes care app | $51M | 12 | April 2023 | $171K | Series B extension / bridge | Lightrock India, HealthQuad, Flipkart Ventures | Active | Strong |
| 41 | HealthSnap | RPM and chronic care platform | $49M | 6 | February 2024 | $25M | Series B | Sands Capital, Comcast Ventures, Florida Funders | Active | Strong |
| 42 | Casana | Smart toilet health monitoring | $46M | 3 | January 2022 | $30M | Series B | Morningside, General Catalyst, Matrix | Active | Strong |
| 43 | Medical Informatics Corp | ICU data and virtual care | $45M | 5 | December 2024 | $5M | Early/other equity | Catalio, Intel Capital, DCVC | Active | Partial |
| 44 | CarePredict | AI senior care monitoring | $42M | 8 | September 2024 | $4M | Series A extension | SV Health Investors, Aspire, Las Olas | Active | Partial |
| 45 | Nutromics | Wearable continuous diagnostic monitoring | $40M | 6 | September 2025 | $5M | Series A / Acceleration | Dexcom Ventures, VU Venture Partners, Artesian | Active | Strong |
| 46 | Optimize Health | Remote care management platform | $40M | 4 | October 2023 | $18M | Series B | Foundry, Escalate Capital Partners, Bonfire Ventures | Active | Strong |
| 47 | 100Plus | Remote monitoring for Medicare patients | $39M | 8 | March 2021 | $25M | Seed | Henry Kravis, George Roberts, Tony Robbins | Acquired | Partial |
| 48 | Cardiac Insight | Wearable ECG analysis devices | $37M | 13 | February 2020 | $8M | Series D | SeaChange Fund, Welch Allyn, WRF Capital | Acquired | Partial |
| 49 | Validic | Health data connectivity platform | $32M | 8 | November 2022 | $12M | Series B extension | Kaiser Permanente Ventures, Greycroft, SJF Ventures | Acquired | Strong |
| 50 | 9am.health | Virtual cardiometabolic clinic | $29M | 3 | February 2024 | $10M | Series A extension | Cigna Ventures, 7wireVentures, Define Ventures | Active | Full |
| 51 | Neteera | Contactless vital-sign monitoring | $28M | 3 | October 2023 | $7M | Series B extension | Aescuvest, Foxconn Technology, Omega Healthcare Investors | Active | Full |
| 52 | Implicity | Remote cardiac monitoring platform | $28M | 3 | April 2022 | $23M | Series A | Crédit Mutuel Innovation, Bpifrance, BNP Paribas Développement | Active | Strong |
| 53 | Sugar.fit | Diabetes reversal programs | $27M | 4 | April 2025 | $1M | Angel / extension | MassMutual Ventures, Cure.fit, Endiya Partners | Active | Partial |
| 54 | Qardio | Connected heart monitoring devices | $27M | 4 | Undisclosed | Undisclosed | Series A / growth equity | Elysia Capital, Eastbourne Investment Group, Medical Technology Venture Partners | Active | Partial |
| 55 | Dozee | Contactless patient monitoring system | $25M | 5 | April 2026 | Undisclosed | Series A | Prime Venture Partners, 3one4 Capital, YourNest | Active | Partial |
| 56 | GraphWear | Needle-free glucose wearable | $25M | 5 | October 2021 | $21M | Series B | Mayfield, MissionBio Capital, Builders VC | Active | Strong |
| 57 | Siren Care | Diabetic foot monitoring socks | $25M | 4 | January 2025 | $10M | Strategic equity | Mölnlycke Health Care, Khosla Ventures, DCM | Active | Strong |
| 58 | Sweetch | AI chronic-care engagement | $24M | 2 | July 2021 | $20M | Series A | Entrée Capital, Tal Capital, Noaber | Active | Partial |
| 59 | Somatix | Wearable AI patient monitoring | $23M | 6 | November 2024 | $1M | Series A extension | Digitalis Ventures, Forefront Analytics | Acquired | Partial |
| 60 | WearLinq | Wireless multi-lead ECG wearable | $21M | 3 | December 2025 | $14M | Series A | AIX Ventures, SpringTide, Amino Capital | Active | Strong |
| 61 | Fitterfly | Digital diabetes therapeutics platform | $19M | 4 | July 2022 | $12M | Series A | Amazon Smbhav, Fireside Ventures, Venture Catalysts | Acquired | Strong |
| 62 | Myia Labs | AI virtual care platform | $17M | 3 | January 2021 | Undisclosed | Series A extension | Mercy Virtual, B Capital Group, Movac | Active | Strong |
| 63 | Limber Health | Hybrid MSK remote monitoring | $16M | 2 | May 2024 | $2M | Series A extension | Blue Venture Fund, Glenview Capital | Acquired | Strong |
| 64 | Vectorious Medical Technologies | Implantable heart pressure sensor | $15M | 2 | March 2018 | $10M | Series B | Broadview Ventures, GEOC, Fresenius | Acquired | Strong |
| 65 | Murj | Cardiac device management software | $14M | 3 | May 2018 | $9M | Series B | Longitude Capital, True Ventures, Social Capital | Active | Strong |
| 66 | Epitel | Wearable EEG seizure monitoring | $13M | 2 | February 2022 | $13M | Series A | Catalyst Health Ventures, Genoa Ventures, Dexcom | Active | Strong |
| 67 | Vector Remote Care | Cardiac device remote monitoring | $13M | 1 | April 2021 | $13M | Series A | Updata Partners | Active | Full |
| 68 | Cloud DX | Virtual care RPM platform | $12M | 5 | March 2025 | Undisclosed | Preferred shares planned | Roosevelt Capital Group investors | IPO | Partial |
| 69 | Elfie | Rewarded chronic-care health app | $12M | 2 | June 2025 | $12M | Series A | White Star Capital, LifeX Ventures, Integra Partners | Active | Strong |
| 70 | Assure Health | Chronic care remote monitoring | $11M | 2 | March 2022 | $9M | Seed | Red Cell Partners, Fanjul Capital | Active | Partial |
| 71 | Acorai | Heart failure pressure monitoring | $11M | 3 | December 2024 | $5M | Seed | Taipei Medical University, Solardis Health Ventures, KHP Ventures | Active | Partial |
| 72 | POPS! Diabetes Care | Smartphone diabetes care system | $10M | 5 | 2019 | Undisclosed | Seed / extension | 30Ventures, Rise of the Rest, Flying Point Industries | Active | Strong |
| 73 | MayaMD | AI patient engagement assistant | $9M | 2 | April 2022 | Undisclosed | Series A | Lux Capital, Prospeq, LG NOVA | Active | Low |
| 74 | Videra Health | Behavioral health video monitoring | $9M | 2 | May 2024 | $6M | Seed II | Peterson Ventures, Mercato Partners, EPIC Ventures | Active | Full |
| 75 | Ventricle Health | Virtual cardiology care platform | $8M | 1 | September 2023 | $8M | Seed | RA Capital Management, Waterline Ventures | Active | Full |
| 76 | BioT | Medical device cloud infrastructure | $7M | 2 | March 2023 | Undisclosed | Seed extension | Bridges Israel, North First Ventures, XT Venture Capital | Active | Partial |
| 77 | Lapsi Health | Digital stethoscope biomarkers | $6M | 3 | January 2025 | $2M | Seed extension | Modi Ventures, Mentors Fund, 1921VC | Active | Strong |
| 78 | NanoVation | Respiratory disease monitoring | $6M | 1 | July 2021 | $6M | Series A | EIC Fund | Active | Strong |
| 79 | Suvera | Virtual chronic-care platform | $5M | 1 | July 2022 | $5M | Seed extension | Morningside Ventures | Active | Full |
| 80 | Novi Health | Chronic disease care platform | $5M | 1 | November 2022 | $5M | Series A | Monk’s Hill Ventures | Active | Full |
| 81 | mySugr | Diabetes management app | $5M | 2 | March 2015 | $5M | Seed | Roche Ventures, iSeed Ventures, XLHealth | Acquired | Strong |
| 82 | Habitual | Type 2 diabetes reversal | $4M | 3 | April 2025 | $1M | Seed extension | Nesta Impact Investments, MMC Ventures, Seedcamp | Active | Strong |
| 83 | Oxitone Medical | Wrist pulse oximetry monitoring | $3M | 1 | September 2014 | $3M | Seed | TMC Innovation, Saints Capital, Connecticut Innovations | Active | Strong |
| 84 | HealthBeats | Remote vitals monitoring platform | $3M | 1 | April 2022 | $3M | Seed | Heritas Capital, SEEDS Capital | Active | Full |
| 85 | CARI Health | Wearable medication monitoring | $3M | 3 | July 2025 | $100K | Seed | SDAC, NuFund, Cove Fund | Active | Strong |
| 86 | Noah Labs | AI heart failure monitoring | $3M | 1 | September 2024 | $3M | Seed | Nina Capital, adesso ventures, Brandenburg Kapital | Active | Partial |
| 87 | Hop Technologies | AI digital biomarkers | $2M | 1 | Undisclosed | $2M | Funding Raised | Iaso Ventures | Active | Low |
| 88 | Nemaura Medical | Non-invasive glucose monitoring | $2M | 1 | December 2018 | $2M | Public offering | Dawson James Securities | IPO | Low |
| 89 | Nanowear | Textile nanosensor remote diagnostics | $2M | 1 | March 2015 | $2M | Seed | MAS Holdings, Social Capital | Active | Partial |
| 90 | PharmD Live | Pharmacist-led chronic care | $1M | 2 | January 2022 | $1M | Seed | Teladoc Health, Village Capital, 1836 Ventures | Active | Partial |
| 91 | Medella Health | Smart glucose contact lenses | $1M | 2 | June 2016 | $1M | Seed | BDC, Garage Technology Ventures, 1517 Fund | Active | Strong |
Key funding trends in the remote patient monitoring market
Insights
- The top 10 remote patient monitoring startups raised about $3.79B, equal to nearly 46% of all funding in this dataset, so capital is highly concentrated
- Diabetes and metabolic-care startups dominate the upper tier, with Beta Bionics, Omada Health, Virta Health, Oviva, Twin Health, Biolinq, and Glooko raising about $2.61B combined
- The largest remote patient monitoring platforms are moving beyond devices, since companies such as Omada Health, Virta Health, Oviva, Cadence, and Hello Heart combine monitoring with ongoing care delivery
- Recent investor appetite is still meaningful, with Oviva, Cadence, Biolinq, FIRE1, and Glooko each raising $100M or more in the latest disclosed financing
- Cardiovascular monitoring remains a durable funding theme, with FIRE1, Eko Health, Hello Heart, BioIntelliSense, Sibel Health, Implicity, and Murj raising about $708M combined
- Wearable biosensor startups still attract large checks, as Biolinq, BioIntelliSense, Sibel Health, Biobeat, and Nutromics raised about $576M across metabolic, cardiac, and vital-sign monitoring
- Strategic healthcare investors appear often in the strongest remote patient monitoring companies, especially CVS Health, Philips, Dexcom, Abbott, Roche, AstraZeneca, and Bayer-linked capital
- Acquisitions mostly happen below the largest independent platforms, with Validic, Fitterfly, Limber Health, Vectorious, mySugr, Bardy Diagnostics, and Preventice Solutions all exiting after smaller funding totals
A few word about our methodology
As you can see, we built a database that ranks startups in the remote patient monitoring market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.
Whenever possible, we prioritized official company communications, since those are usually the most reliable source for funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times, Forbes, MobiHealthNews, Fierce Healthcare, or company investor pages.
We excluded random blogs, unverified websites, and any sources that could not be validated.
When funding rounds were announced in other currencies such as euros, British pounds, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.
Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each startup, visible in the last column.
Here is what they mean.
Full confidence: The company’s equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.
Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.
Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.
Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company’s equity fundraising history.
When the confidence level is too low, we take a conservative approach and flag the company clearly. We don’t want readers to confuse uncertain data with fully verified funding history.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.
Related blog posts
- The main fundraising trends in the remote patient monitoring market
- The most highly valued startups in the remote patient monitoring market
- How healthy is startup funding in the remote patient monitoring market right now?
- All the funding deals in the remote patient monitoring market
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.